Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MLTX | PRESS-RELEASE | bearish | 6/10 | MoonLake Immunotherapeutics priced a $200M underwritten public offering of 9M Class A ordinary shares at $20.00 per shar | Jun 23, 2026 |
| QURE | PRESS-RELEASE | bearish | 6/10 | uniQure priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting approximately | Jun 23, 2026 |
| CELZ | PRESS-RELEASE | bullish | 6/10 | Creative Medical Technology announced FDA clearance to expand its ADAPT Phase 2 trial of CELZ-201 (Olastrocel) for chron | Jun 22, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine announced the successful completion of treatment for all 24 participants in Part A of its Phase I/II | Jun 22, 2026 |
| PVLA | PRESS-RELEASE | bullish | 7/10 | Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat micro | Jun 22, 2026 |
| BBIO | PRESS-RELEASE | neutral | 4/10 | BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will | Jun 22, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy f | Jun 22, 2026 |
| NRXP | PRESS-RELEASE | neutral | 4/10 | NRx Pharmaceuticals announced FDA approval of an Expanded Access Protocol for NRX-101 (D-cycloserine/lurasidone) to augm | Jun 22, 2026 |
| TCRX | PRESS-RELEASE | bullish | 7/10 | TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete don | Jun 22, 2026 |
| LODE | PRESS-RELEASE | bullish | 6/10 | Comstock Inc. announced the sale of 100% of its mining and mineral assets to Mackay Precious Metals Inc. for over $45 mi | Jun 22, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake announced positive Week 52 Phase 3 VELA data for sonelokimab in hidradenitis suppurativa, showing 67.2% HiSCR75 | Jun 21, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under | Jun 19, 2026 |
| CAMP | PRESS-RELEASE | neutral | 2/10 | CAMP4 Therapeutics granted inducement stock options for 39,000 shares to three new hires at $3.96 per share, a routine c | Jun 19, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia Pharmaceuticals reported Q1 2026 EPS of -$0.23, beating consensus estimates of -$0.26 by 9.8%. The filing cover | Jun 19, 2026 |
| CRVO | PRESS-RELEASE | bearish | 7/10 | CervoMed announced a registered direct offering of 2.5M shares at $4.00/share, raising $10M in gross proceeds. The dilut | Jun 18, 2026 |
| BCDA | PRESS-RELEASE, 8-K | neutral | 5/10 | BioCardia issued a shareholder letter following a recent capital raise, outlining key 2026 milestones: a planned Q4 2026 | Jun 18, 2026 |
| DNLI | PRESS-RELEASE | bullish | 6/10 | Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in g | Jun 18, 2026 |
| ALLR | PRESS-RELEASE | neutral | 3/10 | Allarity Therapeutics announced a Trial-in-Progress poster presentation at the ESMO Gynaecological Cancers Congress 2026 | Jun 18, 2026 |
| GRCE | PRESS-RELEASE | bearish | 7/10 | Grace Therapeutics reported fiscal year 2026 results with a reduced net loss of $7.8M ($0.47/share) vs $9.6M ($0.79/shar | Jun 18, 2026 |
| PRME | PRESS-RELEASE | bullish | 6/10 | Prime Medicine announced that New Zealand's Medsafe cleared its Clinical Trial Application for PM577a, an in vivo Prime | Jun 18, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced a new U.S. patent (No. 12,350,242) for its MEAI molecule covering binge behavior regulation | Jun 18, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective killing of b | Jun 18, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech closed a $98M public offering of 26.1M shares at $3.75/share and concurrently announced a $67M private placemen | Jun 18, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech completed a $98M public offering of 26,066,667 shares at $3.75 and concurrently announced a separate $67M priva | Jun 18, 2026 |
| LEGN | PRESS-RELEASE | bearish | 6/10 | Legend Biotech announced a $226M underwritten public offering of 7.7M ADSs at $29.35 per ADS, with a 30-day option for a | Jun 17, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen announced the acquisition of private biotech RayThera for up to $1 billion (upfront plus milestone payments), add | Jun 17, 2026 |
| MSLE | PRESS-RELEASE | neutral | 2/10 | Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with all director nominees elected an | Jun 17, 2026 |
| LXEO | PRESS-RELEASE | neutral | 5/10 | Lexeo Therapeutics reported JAMA Cardiology publication of Phase I/II LX2006 gene therapy data in Friedreich atxia cardi | Jun 17, 2026 |
| SPRO | PRESS-RELEASE | bullish | 8/10 | Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic fo | Jun 17, 2026 |
| ERNA | PRESS-RELEASE | neutral | 5/10 | Ernexa Therapeutics provided a pre-IND progress update on ERNA-101, its lead iMSC therapy for immunologically cold tumor | Jun 17, 2026 |